Mirati Therapeutics Company Profile (NASDAQ:MRTX)

About Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics logoMirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MRTX
  • CUSIP: N/A
  • Web: www.mirati.com
Capitalization:
  • Market Cap: $388.28 million
  • Outstanding Shares: 24,970,000
Average Prices:
  • 50 Day Moving Avg: $10.79
  • 200 Day Moving Avg: $5.83
  • 52 Week Range: $2.70 - $16.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.39
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.32 per share
  • Price / Book: 4.74
Profitability:
  • EBITDA: ($73,470,000.00)
  • Return on Equity: -101.85%
  • Return on Assets: -86.50%
Debt:
  • Current Ratio: 7.87%
  • Quick Ratio: 7.87%
Misc:
  • Average Volume: 1.31 million shs.
  • Beta: 1.76
  • Short Ratio: 5.41
 

Frequently Asked Questions for Mirati Therapeutics (NASDAQ:MRTX)

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings data on Thursday, March, 9th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.97) by $0.02. View Mirati Therapeutics' Earnings History.

Where is Mirati Therapeutics' stock going? Where will Mirati Therapeutics' stock price be in 2017?

10 brokers have issued 1 year price targets for Mirati Therapeutics' shares. Their predictions range from $5.00 to $20.00. On average, they expect Mirati Therapeutics' share price to reach $13.88 in the next twelve months. View Analyst Ratings for Mirati Therapeutics.

What are analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:

  • 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (10/5/2017)
  • 2. Jefferies Group LLC analysts commented, "MRTX reported clinical updates on lead programs, glesatinib and sitravatinib. ID’ing glesatinib’s optimal patient pop (MET amp) as well as better safety w/ lower discontinuation rate on new formulation could start to pay off as more pts enter ph.II, which could help enable them to show whether activity is differentiated. Sitravatinib data remains early." (1/9/2017)

Who are some of Mirati Therapeutics' key competitors?

How do I buy Mirati Therapeutics stock?

Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of Mirati Therapeutics stock can currently be purchased for approximately $15.75.


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mirati Therapeutics (NASDAQ:MRTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $13.88 (11.90% downside)
Consensus Price Target History for Mirati Therapeutics (NASDAQ:MRTX)
Price Target History for Mirati Therapeutics (NASDAQ:MRTX)
Analysts' Ratings History for Mirati Therapeutics (NASDAQ:MRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017SunTrust Banks, Inc.Reiterated RatingBuy$13.00N/AView Rating Details
10/12/2017HC WainwrightReiterated RatingBuy -> Buy$20.00N/AView Rating Details
9/19/2017CIBCInitiated CoverageOutperform -> Outperform$18.00LowView Rating Details
9/19/2017Citigroup Inc.Reiterated RatingBuy$8.00 -> $16.00LowView Rating Details
9/19/2017CannInitiated CoverageOutperformHighView Rating Details
9/18/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$18.00MediumView Rating Details
9/15/2017Leerink SwannBoost Price TargetMkt Perform -> Market Perform$7.00 -> $9.00N/AView Rating Details
8/4/2017Jefferies Group LLCSet Price TargetHold$5.00LowView Rating Details
11/18/2016Avondale PartnersDowngradeOutperform -> Market PerformN/AView Rating Details
11/4/2016WedbushReiterated RatingOutperform$12.00N/AView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetHold$7.00N/AView Rating Details
6/6/2016Barclays PLCLower Price TargetOverweight$41.00 -> $27.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Mirati Therapeutics (NASDAQ:MRTX)
Earnings by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Earnings History by Quarter for Mirati Therapeutics (NASDAQ MRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017Q4 2016($0.97)($0.99)ViewN/AView Earnings Details
8/4/2016Q2($1.15)($1.11)ViewN/AView Earnings Details
5/5/2016Q1($0.99)($1.13)ViewN/AView Earnings Details
3/9/2016Q4($1.03)($0.96)ViewN/AView Earnings Details
11/6/2015Q3 2015($0.88)($1.11)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.74)($0.95)ViewN/AView Earnings Details
5/6/2015Q1 2015($0.71)($0.77)ViewN/AView Earnings Details
3/11/2015Q414($1.00)($0.77)ViewN/AView Earnings Details
11/10/2014Q314($0.77)($0.72)ViewN/AView Earnings Details
8/8/2014Q214($0.69)($0.82)ViewN/AView Earnings Details
3/18/2014Q413($0.66)($0.97)ViewN/AView Earnings Details
11/12/2013Q313($0.78)($2.95)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mirati Therapeutics (NASDAQ:MRTX)
2017 EPS Consensus Estimate: ($3.56)
2018 EPS Consensus Estimate: ($3.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.08)($0.80)($0.91)
Q2 20173($1.10)($0.74)($0.89)
Q3 20174($1.12)($0.76)($0.87)
Q4 20174($1.16)($0.75)($0.89)
Q1 20181($0.77)($0.77)($0.77)
Q2 20181($0.79)($0.79)($0.79)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mirati Therapeutics (NASDAQ:MRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mirati Therapeutics (NASDAQ:MRTX)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 60.13%
Insider Trades by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Insider Trades by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Jamie ChristensenSVPSell4,000$14.00$56,000.00View SEC Filing  
9/15/2017Jamie ChristensenSVPSell770$12.00$9,240.00View SEC Filing  
1/26/2017Ltd. BraslynMajor ShareholderBuy48,169$5.45$262,521.05View SEC Filing  
1/25/2017Ltd. BraslynMajor ShareholderBuy30,600$5.42$165,852.00View SEC Filing  
1/24/2017Ltd. BraslynMajor ShareholderBuy27,682$5.32$147,268.24View SEC Filing  
1/23/2017Ltd. BraslynMajor ShareholderBuy19,251$5.27$101,452.77View SEC Filing  
1/20/2017Ltd. BraslynMajor ShareholderBuy61,158$5.46$333,922.68View SEC Filing  
1/17/2017Ltd. BraslynMajor ShareholderBuy119,887$5.50$659,378.50View SEC Filing  
1/6/2017Boxer Capital, LlcMajor ShareholderBuy286,163$5.60$1,602,512.80View SEC Filing  
6/14/2016Charles M BaumCEOBuy20,000$7.05$141,000.00View SEC Filing  
6/9/2016Bros. Advisors Lp BakerMajor ShareholderSell999,358$9.41$9,403,958.78View SEC Filing  
6/7/2016Ltd. BraslynMajor ShareholderBuy376,902$9.96$3,753,943.92View SEC Filing  
5/6/2016Ltd. BraslynMajor ShareholderBuy65,782$18.21$1,197,890.22View SEC Filing  
3/28/2016Ltd. BraslynMajor ShareholderBuy20,848$19.36$403,617.28View SEC Filing  
3/18/2016Ltd. BraslynMajor ShareholderBuy1,166$19.34$22,550.44View SEC Filing  
1/15/2016Mark J. GergenCOOSell10,000$25.92$259,200.00View SEC Filing  
9/16/2015Bros. Advisors Lp BakerMajor ShareholderBuy150,000$45.00$6,750,000.00View SEC Filing  
5/26/2015Jamie ChristensenSVPSell4,750$28.07$133,332.50View SEC Filing  
3/5/2015Jamie ChristensenSVPSell6,000$25.41$152,460.00View SEC Filing  
2/19/2015Jamie ChristensenSVPSell4,750$22.84$108,490.00View SEC Filing  
2/3/2015Orbimed Advisors LlcMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
1/29/2015Bros. Advisors Lp BakerMajor ShareholderBuy425,000$20.00$8,500,000.00View SEC Filing  
7/1/2014Orbimed Advisors LlcMajor ShareholderSell107,332$21.66$2,324,811.12View SEC Filing  
11/26/2013Charles M BaumCEOBuy5,000$16.96$84,800.00View SEC Filing  
10/29/2013Orbimed Advisors LlcMajor ShareholderBuy125,000$17.50$2,187,500.00View SEC Filing  
10/24/2013Tang Capital Partners LpMajor ShareholderBuy57,143$17.50$1,000,002.50View SEC Filing  
9/20/2013Tang Capital Partners LpMajor ShareholderSell36,898$16.34$602,913.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Mirati Therapeutics (NASDAQ:MRTX)
Latest Headlines for Mirati Therapeutics (NASDAQ:MRTX)
Source:
DateHeadline
thestreet.com logoMRTX Crosses Above Average Analyst Target
www.thestreet.com - October 21 at 6:41 AM
americanbankingnews.com logoComparing VBI Vaccines (VBIV) & Mirati Therapeutics (MRTX)
www.americanbankingnews.com - October 21 at 6:40 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Forecasted to Post FY2018 Earnings of ($2.85) Per Share
www.americanbankingnews.com - October 19 at 2:28 PM
nasdaq.com logo4 Biotech & Health Stocks to Watch
www.nasdaq.com - October 19 at 6:27 AM
finance.yahoo.com logoFour Biotech And Health Care Breakouts
finance.yahoo.com - October 19 at 6:27 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 18 at 1:16 PM
americanbankingnews.com logoMirati Therapeutics' (MRTX) "Buy" Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - October 12 at 7:00 PM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Now Covered by HC Wainwright
www.americanbankingnews.com - October 12 at 8:02 AM
americanbankingnews.com logoZacks Investment Research Lowers Mirati Therapeutics, Inc. (MRTX) to Sell
www.americanbankingnews.com - October 8 at 1:06 PM
americanbankingnews.com logoJamie Christensen Sells 4,000 Shares of Mirati Therapeutics, Inc. (MRTX) Stock
www.americanbankingnews.com - October 6 at 8:16 PM
americanbankingnews.com logoZacks: Analysts Anticipate Mirati Therapeutics, Inc. (MRTX) Will Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - October 6 at 4:36 PM
investopedia.com logoWhy Biotech's Rally May Push These 8 Stocks Even Higher - Investopedia
www.investopedia.com - October 5 at 9:17 AM
americanbankingnews.com logoComparing Mirati Therapeutics (MRTX) & Its Competitors
www.americanbankingnews.com - October 4 at 10:38 AM
americanbankingnews.com logoMirati Therapeutics (MRTX) & Its Rivals Head-To-Head Survey
www.americanbankingnews.com - October 3 at 10:22 PM
americanbankingnews.com logoAnalyzing Mirati Therapeutics (MRTX) and Its Rivals
www.americanbankingnews.com - September 24 at 6:34 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 23 at 11:04 AM
seekingalpha.com logoMirati Brings Hope With Its Stellar Performance - Mirati Therapeutics ... - Seeking Alpha
seekingalpha.com - September 23 at 8:23 AM
americanbankingnews.com logoAnalysts Offer Predictions for Mirati Therapeutics, Inc.'s Q3 2017 Earnings (MRTX)
www.americanbankingnews.com - September 21 at 7:56 AM
finance.yahoo.com logoMirati Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
finance.yahoo.com - September 20 at 6:30 AM
finance.yahoo.com logoMirati Therapeutics To Present At Upcoming Healthcare Conferences
finance.yahoo.com - September 20 at 6:30 AM
americanbankingnews.com logoMirati Therapeutics (MRTX) vs. Its Rivals Head to Head Review
www.americanbankingnews.com - September 20 at 6:14 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Now Covered by Cann
www.americanbankingnews.com - September 19 at 8:20 PM
americanbankingnews.com logoMirati Therapeutics' (MRTX) "Buy" Rating Reiterated at Citigroup Inc.
www.americanbankingnews.com - September 19 at 3:16 PM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Earns Outperform Rating from Analysts at CIBC
www.americanbankingnews.com - September 19 at 2:32 PM
thestreet.com logoMirati Therapeutics Reaches Analyst Target Price
www.thestreet.com - September 18 at 11:26 PM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Earns Outperform Rating from Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 18 at 7:00 PM
finance.yahoo.com logoMirati Therapeutics Sitravatinib Data, Explained
finance.yahoo.com - September 16 at 6:40 AM
finance.yahoo.com logoIs It Too Late To Buy Mirati Therapeutics Inc (MRTX)?
finance.yahoo.com - September 16 at 6:40 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) PT Raised to $9.00 at Leerink Swann
www.americanbankingnews.com - September 15 at 7:26 PM
americanbankingnews.com logoHead-To-Head Contrast: Mirati Therapeutics (MRTX) versus Its Peers
www.americanbankingnews.com - September 15 at 2:30 PM
streetinsider.com logoMirati Therapeutics (MRTX) Reports Positive Preliminary Data From On-Going Clinical Trials of Sitravatinib in Non-Small Cell Lung Cancer
www.streetinsider.com - September 14 at 9:17 PM
seekingalpha.com logoMirati Therapeutics +63% on clinical trial data for lung cancer treatment
seekingalpha.com - September 14 at 6:25 PM
americanbankingnews.com logoComparing Mirati Therapeutics (MRTX) and Its Competitors
www.americanbankingnews.com - September 13 at 8:10 PM
americanbankingnews.com logoContrasting Mirati Therapeutics (MRTX) and its Peers
www.americanbankingnews.com - September 11 at 2:24 AM
finance.yahoo.com logoSitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer
finance.yahoo.com - September 7 at 6:24 AM
finance.yahoo.com logoMirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference
finance.yahoo.com - August 31 at 7:29 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 29 at 10:58 AM
americanbankingnews.com logoShort Interest in Mirati Therapeutics, Inc. (NASDAQ:MRTX) Expands By 40.5%
www.americanbankingnews.com - August 13 at 1:46 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (NASDAQ:MRTX) Given a $5.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - August 5 at 9:36 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 4 at 10:44 AM
finance.yahoo.com logoMirati Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 5:26 AM
finance.yahoo.com logoMirati reports 2Q loss
finance.yahoo.com - August 4 at 5:26 AM
americanbankingnews.com logo-$0.81 Earnings Per Share Expected for Mirati Therapeutics, Inc. (NASDAQ:MRTX) This Quarter
www.americanbankingnews.com - July 24 at 8:22 PM
finance.yahoo.com logoMirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher
finance.yahoo.com - July 19 at 1:54 AM
americanbankingnews.com logoShort Interest in Mirati Therapeutics, Inc. (MRTX) Decreases By 49.0%
www.americanbankingnews.com - July 17 at 7:24 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 10 at 10:41 AM
finance.yahoo.com logoMirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York
finance.yahoo.com - July 5 at 8:50 PM
marketbeat.com logoMirati reports 1Q loss
marketbeat.com - May 4 at 6:57 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
biz.yahoo.com - March 27 at 6:10 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 6:27 PM

Social

Chart

Mirati Therapeutics (MRTX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.